SpineThera Patent Issued

SpineThera, a privately held, pre-clinical stage pharmaceutical company, announced today that the United States Patent and Trade Mark Office has issued US Patent 8,927,529 covering sustained-release, injectable drug formulations for the treatment of back pain.

"Our novel, sustained-release technology is designed for the specific and unique requirements of injectable drugs intended for administration in and near the spine," said Jeff Missling, SpineThera's founder and CEO. "Receiving this patent is an important step in the development of our company and its technology."